Literature DB >> 17413691

Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.

Karin J Metzner1, Kristina Allers, Pia Rauch, Thomas Harrer.   

Abstract

OBJECTIVE: Efficient antiretroviral therapy (ART) of HIV-1 infection reduces the viral load to undetectable levels and restores the immune system. However, therapy failure appears in a substantial fraction of patients and is mostly associated with the appearance of drug-resistant viruses. It is still not clear when the drug pressure leads to the earliest selection and appearance of drug-resistant HIV-1 populations. In this study, we wanted to determine whether drug-resistant viruses are already selected during viral decline within the first months of ART. DESIGN AND METHODS: Fifteen mostly chronically HIV-1 infected patients were included. None had received ART prior to this study. The selection of three key resistance mutations, L90M (protease), K103N and M184V (reverse transcriptase), were measured by allele-specific real-time PCR allowing us to track minority quasispecies with a discriminative power of 0.01-0.2%.
RESULTS: Drug-resistant HIV-1 variants were found in 7/15 patients (46.7%) prior to ART. Rapid selection of drug resistance was detected in six patients (40%) independent of the presence of drug-resistant HIV-1 prior to ART. The risk for the selection of drug resistant viruses was correlated with the time until viral load became undetectable (P = 0.02). Besides the proportional increment of drug-resistant viruses, we observed in two patients a quantitative increase of this virus population while the total viral load decreased.
CONCLUSIONS: Drug-resistant viruses can be selected and replicate even in the first weeks of suppressive ART, thus, intensification of ART during the initial treatment period should be considered and further evaluated in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413691     DOI: 10.1097/QAD.0b013e3280121ac6

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

Review 1.  Novel paradigms for drug discovery: computational multitarget screening.

Authors:  Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala
Journal:  Trends Pharmacol Sci       Date:  2008-01-10       Impact factor: 14.819

2.  Linked dual-class HIV resistance mutations are associated with treatment failure.

Authors:  Valerie F Boltz; Wei Shao; Michael J Bale; Elias K Halvas; Brian Luke; James A McIntyre; Robert T Schooley; Shahin Lockman; Judith S Currier; Fred Sawe; Evelyn Hogg; Michael D Hughes; Mary F Kearney; John M Coffin; John W Mellors
Journal:  JCI Insight       Date:  2019-10-03

Review 3.  Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.

Authors:  Tracy L Lehman; Kevin P O'Halloran; Edward A Hoover; Paul R Avery
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

4.  Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Authors:  Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

5.  Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

Authors:  Karin J Metzner; Christine Leemann; Francesca Di Giallonardo; Christina Grube; Alexandra U Scherrer; Dominique Braun; Herbert Kuster; Rainer Weber; Huldrych F Guenthard
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

6.  Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.

Authors:  Pierre Delobel; Adrien Saliou; Florence Nicot; Martine Dubois; Stéphanie Trancart; Philippe Tangre; Jean-Pierre Aboulker; Anne-Marie Taburet; Jean-Michel Molina; Patrice Massip; Bruno Marchou; Jacques Izopet
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

7.  Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

Authors:  Charlotte Charpentier; Laurence Weiss
Journal:  Infect Drug Resist       Date:  2010-10-13       Impact factor: 4.003

8.  Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

Authors:  Joanne D Stekler; Giovanina M Ellis; Jacquelyn Carlsson; Braiden Eilers; Sarah Holte; Janine Maenza; Claire E Stevens; Ann C Collier; Lisa M Frenkel
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

9.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Authors:  Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

10.  Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.

Authors:  Alexandra U Scherrer; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Hansjakob Furrer; Alexandra Calmy; Matthias Cavassini; Luigia Elzi; Pietro L Vernazza; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.